1. Adachi JD, Loannidis G, Berger C, Joseph L, Papaioannou A, Pickard L, et al. The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada. Osteoporos Int. 12:903–908. 2001.
Article
2. Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 22:465–475. 2007.
Article
3. Cho DC, Kim KT, Jeon Y, Sung JK. A synergistic bone sparing effect of curcumin and alendronate in ovariectomized rat. Acta Neurochir (Wien). 154:2215–2223. 2012.
Article
4. Ersan N, van Ruijven LJ, Bronckers AL, Olgaç V, Ilgüy D, Everts V. Teriparatide and the treatment of bisphosphonate-related osteonecrosis of the jaw: a rat model. Dentomaxillofac Radiol. 43:20130144. 2014.
Article
5. Ferretti M, Bertoni L, Cavani F, Zavatti M, Resca E, Carnevale G, et al. Influence of ferutinin on bone metabolism in ovariectomized rats. II: role in recovering osteoporosis. J Anat. 217:48–56. 2010.
Article
6. French DL, Muir JM, Webber CE. The ovariectomized, mature rat model of postmenopausal osteoporosis: an assessment of the bone sparing effects of curcumin. Phytomedicine. 15:1069–1078. 2008.
Article
7. Giuliani N, Pedrazzoni M, Passeri G, Negri G, Impicciatore M, Girasole G. Bisphosphonates stimulate the production of basic fibroblast growth factor and the formation of bone marrow precursors of osteoblasts. New findings about their mechanism of action. Minerva Med. 89:249–258. 1998.
8. Horcajada-Molteni MN, Crespy V, Coxam V, Davicco MJ, Rémésy C, Barlet JP. Rutin inhibits ovariectomy-induced osteopenia in rats. J Bone Miner Res. 15:2251–2258. 2000.
Article
9. Isai M, Sakthivel M, Ramesh E, Thomas PA, Geraldine P. Prevention of selenite-induced cataractogenesis by rutin in Wistar rats. Mol Vis. 15:2570–2577. 2009.
10. Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 9:1137–1141. 1994.
Article
11. Kaptoge S, Beck TJ, Reeve J, Stone KL, Hillier TA, Cauley JA, et al. Prediction of incident hip fracture risk by femur geometry variables measured by hip structural analysis in the study of osteoporotic fractures. J Bone Miner Res. 23:1892–1904. 2008.
Article
12. Korkmaz A, Kolankaya D. Protective effect of rutin on the ischemia/ reperfusion induced damage in rat kidney. J Surg Res. 164:309–315. 2010.
Article
13. Kyung TW, Lee JE, Shin HH, Choi HS. Rutin inhibits osteoclast formation by decreasing reactive oxygen species and TNF-alpha by inhibiting activation of NF-kappaB. Exp Mol Med. 40:52–58. 2008.
Article
14. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest. 106:1481–1488. 2000.
Article
15. Lumachi F, Frigo AC, Basso U, Tombolan V, Ermani M. Estrogen therapy and risk of breast cancer in postmenopausal women: a case-control study and results of a multivariate analysis. Menopause. 17:524–528. 2010.
16. Manach C, Morand C, Demigné C, Texier O, Régérat F, Rémésy C. Bioavailability of rutin and quercetin in rats. FEBS Lett. 409:12–16. 1997.
Article
17. Middleton ET, Steel SA, Aye M, Doherty SM. The effect of prior bisphosphonate therapy on the subsequent BMD and bone turnover response to strontium ranelate. J Bone Miner Res. 25:455–462. 2010.
Article
18. Omi N, Ezawa I. The effect of ovariectomy on bone metabolism in rats. Bone. 17:163S–168S. 1995.
Article
19. Pabon M, Tamboli C, Tamboli S, Acosta S, De La Pena I, Sanberg PR, et al. Estrogen replacement therapy for stroke. Cell Med. 6:111–122. 2014.
Article
20. Palumbo C, Ferretti M, Bertoni L, Cavani F, Resca E, Casolari B, et al. Influence of ferutinin on bone metabolism in ovariectomized rats. I: role in preventing osteoporosis. J Bone Miner Metab. 27:538–545. 2009.
Article
21. Pazianas M, Abrahamsen B. Safety of bisphosphonates. Bone. 49:103–110. 2011.
Article
22. Reszka AA, Rodan GA. Mechanism of action of bisphosphonates. Curr Osteoporos Rep. 1:45–52. 2003.
Article
23. Shin YH, Cho DC, Yu SH, Kim KT, Cho HJ, Sung JK. Histomorphometric analysis of the spine and femur in ovariectomized rats using micro-computed tomographic scan. J Korean Neurosurg Soc. 52:1–6. 2012.
Article
24. Songpatanasilp T, Mumtaz M, Chhabra H, Yu M, Sorsaburu S. Back pain in patients with severe osteoporosis on teriparatide or antiresorptives: a prospective observational study in a multiethnic population. Singapore Med J. 55:493–501. 2014.
Article
25. Thompson DD, Simmons HA, Pirie CM, Ke HZ. FDA guidelines and animal models for osteoporosis. Bone. 17:125S–133S. 1995.
Article
26. Watts NB, Nolan JC, Brennan JJ, Yang HM; ESTRATAB/Osteoporosis Study Group. Esterified estrogen therapy in postmenopausal women. Relationships of bone marker changes and plasma estradiol to BMD changes: a two-year study. Menopause. 7:375–382. 2000.
Article
27. Weber M, Uehlinger K, Gerber H. Osteoporotic vertebral compression fracture causing neurologic deficit. J Clin Rheumatol. 8:166–173. 2002.
Article
28. Yang MW, Wang TH, Yan PP, Chu LW, Yu J, Gao ZD, et al. Curcumin improves bone microarchitecture and enhances mineral density in APP/PS1 transgenic mice. Phytomedicine. 18:205–213. 2011.
Article
29. Zhang Q, Chen B, Yan F, Guo J, Zhu X, Ma S, et al. Interleukin-10 inhibits bone resorption: a potential therapeutic strategy in periodontitis and other bone loss diseases. Biomed Res Int. 2014:284836. 2014.
Article